var docs;if (!docs) docs =[]; docs["96"]={"9651":"<p><b>Title</b> Repaglinide / Clopidogrel</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: The management of this interaction differs between US and Canadian labeling.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Clopidogrel may increase the serum concentration of Repaglinide. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid concomitant use of clopidogrel and repaglinide if possible. For patients receiving clopidogrel who are to be started on repaglinide, initiate repaglinide at 0.5 mg with each meal, and titrate repaglinide dose according to blood glucose concentrations. Do not exceed a total repaglinide daily dose of 4 mg. Monitor for increased repaglinide effects (eg, hypoglycemia) if combined with clopidogrel. Some non-US labeling states that this combination is contraindicated.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 9 healthy volunteers, coadministration of clopidogrel (300 mg single dose followed by 75 mg daily for 3 days) and repaglinide (0.25 mg single dose on days 1 and 3) resulted in an increase in repaglinide AUC by 5.1-fold and 3.9-fold, on days 1 and 3, respectively.<sup>1</sup> On day 1, the repaglinide maximum serum concentration (Cmax) increased 2.5-fold and the half-life increased 44%. On day 3, the repaglinide Cmax and half-life increased by 2-fold and 25%, respectively.<sup>1</sup> The ratio of the clopidogrel M4 metabolite (formed by CYP2C8) to parent drug was reduced by 81% and 73%, on days 1 and 3, respectively.<sup>1</sup> Hypoglycemia was observed during coadministration.<br><br>Based on this study, Canadian labeling has been updated to list use of clopidogrel and repaglinide as contraindicated due to the risk of increased repaglinide exposure and hypoglycemia.<sup>2</sup> The U.S. clopidogrel and repaglinide labels recommend avoiding the combination if possible and recommend a repaglinide dose reduction when use with clopidogrel is necessary.<sup>3,4</sup><br><br>The mechanism of this interaction is that the glucuronide metabolite of clopidogrel inhibits CYP2C8, an enzyme responsible for repaglinide metabolism.<sup>1,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tornio A, Filppula AM, Kailari O, et al. Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions. <i>Clin Pharmacol Ther</i>. 2014;96(4):498-507. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24971633\">[PubMed 24971633]</a></p>\n<p>2. Gluconorm (repaglinide) [product monograph]. Mississauga, Ontario, Canada: Novo Nordisk Canada; June 2015.</p>\n<p>3. Plavix (clopidogrel) [prescribing information]. Bridgewater, NJ: Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership; September 2016.</p>\n<p>4. Prandin (repaglinide) [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc.; February 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9652":"<p><b>Title</b> DULoxetine / CYP2D6 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2D6 Inhibitors (Strong) may increase the serum concentration of DULoxetine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased duloxetine effects/toxicities if combined with a strong CYP2D6 inhibitor.</p>\n<div>\n <p><b>CYP2D6 Inhibitors (Strong) Interacting Members</b> FLUoxetine, PARoxetine, QuiNIDine, Tipranavir</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 9 healthy volunteers, the strong CYP2D6 inhibitor paroxetine (20 mg daily for 20 days) increased the duloxetine (40 mg daily for 5 days) AUC and maximum serum concentration by 59% and 60%, respectively.<sup>1,2</sup><br><br>Prescribing information for duloxetine states that use of strong CYP2D6 inhibitors may increase duloxetine serum concentrations and effects.<sup>2</sup> <br><br>The mechanism of this interaction is CYP2D6 inhibition by strong CYP2D6 inhibitors, an enzyme responsible for some, but not all, of duloxetine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Skinner MH, Kuan HY, Pan A, et al. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. <i>Clin Pharmacol Ther</i>. 2003;73(3):170-177. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12621382\">[PubMed 12621382]</a></p>\n<p>2. Cymbalta (duloxetine) [prescribing information]. Indianapolis, IN: Lilly USA LLC; November 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9653":"<p><b>Title</b> Antihepaciviral Combination Products / CYP3A4 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Moderate) may decrease the serum concentration of Antihepaciviral Combination Products. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The use of antihepaciviral combination products (ombitasvir/paritaprevir/ritonavir and ombitasvir/paritaprevir/ritonavir/dasabuvir) and moderate CYP3A4 inducers is contraindicated.</p>\n<div>\n <p><b>CYP3A4 Inducers (Moderate) Interacting Members</b> Bexarotene (Systemic), Bosentan, Dabrafenib, Efavirenz, Eslicarbazepine, Etravirine, Modafinil, Nafcillin, Rifapentine, St John's Wort</p>\n <p><b>Antihepaciviral Combination Products Interacting Members</b> Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in product labeling, the strong CYP3A4 inducer carbamazepine (200 mg once daily titrated to 200 mg twice daily) decreased the AUC of ombitasvir 31%, paritaprevir 70%, ritonavir 87%, and dasabuvir 70% when given with the ombitasvir/paritaprevir/ritonavir/dasabuvir combination product in 12 healthy volunteers.<sup>1,2</sup> The maximum serum concentration of ombitasvir, paritaprevir, ritonavir, and dasabuvir decreased 31%, 66%, 83%, and 55%, respectively.<sup>1,2</sup><br><br>Product labeling for antihepaciviral combination products (ombitasvir/paritaprevir/ritonavir and ombitasvir/paritaprevir/ritonavir/dasabuvir) state that use with moderate CYP3A4 inducers is contraindicated due to the potential for decreased exposure of each component and the loss of therapeutic efficacy.<sup>1,2</sup><br><br>The mechanism of this interaction is likely increased CYP3A4 mediated metabolism, an enzyme responsible for paritaprevir, ritonavir, and dasabuvir metabolism. Induction of P-glycoprotein may also play a role.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>2. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9654":"<p><b>Title</b> Antihepaciviral Combination Products / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Antihepaciviral Combination Products. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The use of antihepaciviral combination products (ombitasvir/paritaprevir/ritonavir with or without dasabuvir) and strong CYP3A4 inducers is contraindicated.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n <p><b>Antihepaciviral Combination Products Interacting Members</b> Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in product labeling, the strong CYP3A4 inducer carbamazepine (200 mg once daily titrated to 200 mg twice daily) decreased the AUC of ombitasvir 31%, paritaprevir 70%, ritonavir 87%, and dasabuvir 70% when given with the ombitasvir/paritaprevir/ritonavir/dasabuvir combination product in 12 healthy volunteers.<sup>1,2</sup> The maximum serum concentration of ombitasvir, paritaprevir, ritonavir, and dasabuvir decreased 31%, 66%, 83%, and 55%, respectively.<sup>1,2</sup><br><br>Product labeling for antihepaciviral combination products (ombitasvir/paritaprevir/ritonavir and ombitasvir/paritaprevir/ritonavir/dasabuvir) state that use with strong CYP3A4 inducers is contraindicated due to decreased exposure of each component and the potential loss of therapeutic efficacy.<sup>1,2</sup><br><br>The mechanism of this interaction is likely increased CYP3A4 mediated metabolism, an enzyme responsible for paritaprevir, ritonavir, and dasabuvir metabolism. Induction of P-glycoprotein and CYP2C8 may also play a role.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>2. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9655":"<p><b>Title</b> Antihepaciviral Combination Products / Ethinyl Estradiol</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ethinyl Estradiol may enhance the hepatotoxic effect of Antihepaciviral Combination Products. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent use of ethinyl estradiol with antihepaciviral combination products is contraindicated. Use of ethinyl estradiol must be discontinued prior to use of this combination; ethinyl estradiol can be restarted 2 weeks after cessation of the antihepaciviral combination product. It is unclear if other estrogens convey a similar increase in risk, but the limited available data suggest no significant increase in risk. Any such combinations should be used with caution.</p>\n<div>\n <p><b>Antihepaciviral Combination Products Interacting Members</b> Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p>\n</div> \n<p><b>Discussion</b> The incidence of elevated alanine aminotransferase (ALT) concentrations in patients taking the ombitasvir/paritaprevir/ritonavir/dasabuvir or ombitasvir/paritaprevir/ritonavir combination products was significantly higher among those who were also treated with ethinyl estradiol.<sup>1,2</sup> The incidence of ALT concentrations at least 5 times the upper limit of normal with use of ombitasvir/paritaprevir/ritonavir/dasabuvir was approximately 1%, but among the small number of patients also using ethinyl estradiol the incidence was 25% (4/16).<sup>1</sup> Available data suggest that a similar risk among patients using other estrogens (3%; 2/59) may be possible.<br><br>The specific mechanism for this potential interaction is unknown. Similarly, whether this increased risk is attributed to one or multiple components in the antihepaciviral combination products is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>2. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9657":"<p><b>Title</b> Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir / CYP2C8 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP2C8 Inhibitors (Strong) may increase the serum concentration of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir. Specifically, the serum concentrations of dasabuvir may increase significantly. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The concomitant use of ombitasvir/paritaprevir/ritonavir/dasabuvir and strong CYP2C8 inhibitors is contraindicated and should be avoided.</p>\n<div>\n <p><b>CYP2C8 Inhibitors (Strong) Interacting Members</b> Gemfibrozil</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the ombitasvir/paritaprevir/ritonavir/dasabuvir prescribing information, the concomitant use of paritaprevir/ritonavir/dasabuvir and the strong CYP2C8 inhibitor gemfibrozil (600 mg twice daily) increased the dasabuvir AUC and maximum serum concentration 11.3-fold and 2.0-fold, respectively.<sup>1</sup><br><br>The prescribing information for ombitasvir/paritaprevir/ritonavir/dasabuvir states that due to the risk of increased QTc prolongation associated with increased dasabuvir exposure, the use of gemfibrozil or any other strong CYP2C8 inhibitor with ombitasvir/paritaprevir/ritonavir/dasabuvir is contraindicated.<br><br>The mechanism of this interaction is CYP2C8 inhibition by gemfibrozil, an enzyme responsible for dasabuvir metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9658":"<p><b>Title</b> Digoxin / Ombitasvir, Paritaprevir, and Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ombitasvir, Paritaprevir, and Ritonavir may increase the serum concentration of Digoxin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> When initiating the ombitasvir/paritaprevir/ritonavir combination product in patients taking digoxin, decrease the digoxin dose by 30% to 50% and monitor serum digoxin levels to determine further dose adjustments.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the ombitasvir/paritaprevir/ritonavir prescribing information, the concomitant administration of ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg daily) with digoxin (0.5 mg single oral dose) increased the digoxin AUC, maximum serum concentration, and minimum serum concentration 36%, 58%, and 24%, respectively.<sup>1</sup><br><br>Product labeling for ombitasvir/paritaprevir/ritonavir states that when ombitasvir/paritaprevir/ritonavir is initiated in patients taking digoxin, the digoxin dose should be reduced by 30% to 50% and monitoring of serum digoxin levels is recommended.<sup>1</sup><br><br>The mechanism of this interaction is likely inhibition of P-glycoprotein, a transporter responsible for digoxin disposition, by ombitasvir/paritaprevir/ritonavir.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9660":"<p><b>Title</b> Midazolam / Antihepaciviral Combination Products</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: Oral midazolam is contraindicated with antihepaciviral combination products. Intravenous midazolam should be used with caution.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Antihepaciviral Combination Products may increase the serum concentration of Midazolam. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use of oral midazolam is contraindicated with antihepaciviral combination products. Intravenous midazolam should be used with caution in a setting equipped to appropriately monitor for and treat any excessive response to midazolam (eg, sedation, respiratory depression). Reduced doses of intravenous midazolam should be considered, particularly if multiple doses may be used.</p>\n<div>\n <p><b>Antihepaciviral Combination Products Interacting Members</b> Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p>\n</div> \n<p><b>Discussion</b> Several studies in healthy volunteers and HIV-infected patients have reported substantial increases (5- to 28-fold) in midazolam AUC and/or 65% to 96% reductions in midazolam oral clearance when oral midazolam was given with ritonavir or ritonavir-boosted doses of lopinavir, saquinavir, or tipranavir.<sup>1,2,3,4,5,6,7</sup> Studies of intravenous midazolam have also reported clinically meaningful increases in midazolam AUC (1.5- to 5.1-fold) and/or decreased midazolam clearance (76% to 77%) with concurrent ritonavir.<sup>5,6,7</sup><br><br>Prescribing information for antihepaciviral combination products states that coadministration with oral midazolam is contraindicated due to the risk of prolonged or increased sedation and/or respiratory depression.<sup>8,9</sup><br><br>The mechanism of this interaction is inhibition of the CYP3A-mediated metabolism of midazolam by antihepaciviral combination products. The interaction with oral midazolam is likely of greater magnitude due to inhibition of CYP3A in both the intestine and liver, and the resultant decrease in first pass metabolism of midazolam.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Greenblatt DJ, Peters DE, Oleson LE, et al. Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase. <i>Br J Clin Pharmacol</i>. 2009;68(6):920-927. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20002087\">[PubMed 20002087]</a></p>\n<p>2. Schmitt C, Hofmann C, Riek M, Patel A, Zwanziger E. Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe. <i>Pharmacotherapy</i>. 2009;29(10):1175-1181. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19792991\">[PubMed 19792991]</a></p>\n<p>3. Knox TA, Oleson L, von Moltke LL, Kaufman RC, Wanke CA, Greenblatt DJ. Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis. <i>J Acquir Immune Defic Syndr</i>. 2008;49(4):358-368. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19186349\">[PubMed 19186349]</a></p>\n<p>4. Mathias AA, West S, Hui J, Kearney BP. Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. <i>Clin Pharmacol Ther</i>. 2009;85(1):64-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18815591\">[PubMed 18815591]</a></p>\n<p>5. Yeh RF, Gaver VE, Patterson KB, et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. <i>J Acquir Immune Defic Syndr</i>. 2006;42(1):52-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16639344\">[PubMed 16639344]</a></p>\n<p>6. Dumond JB, Vourvahis M, Rezk NL, et al. A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. <i>Clin Pharmacol Ther</i>. 2010;87(6):735-742. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20147896\">[PubMed 20147896]</a></p>\n<p>7. Wyen C, Fuhr U, Frank D, et al. Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. <i>Clin Pharmacol Ther</i>. 2008;84(1):75-82. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18183034\">[PubMed 18183034]</a></p>\n<p>8. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>9. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9661":"<p><b>Title</b> Ergot Derivatives / Antihepaciviral Combination Products</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Antihepaciviral Combination Products may increase the serum concentration of Ergot Derivatives. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The use of antihepaciviral combination products and ergot derivatives should be avoided. Concomitant use contraindicated in product labeling.</p>\n<div>\n <p><b>Ergot Derivatives Interacting Members</b> Bromocriptine, Dihydroergotamine, Ergoloid Mesylates, Ergonovine, Ergotamine, Methylergonovine<br><b>Exceptions</b> Cabergoline, Nicergoline, Pergolide</p>\n <p><b>Antihepaciviral Combination Products Interacting Members</b> Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p>\n</div> \n<p><b>Discussion</b> Many published reports describe cases of ergot toxicity (including ischemia of an extremity, coma, and death) associated with concurrent use of an ergot alkaloid and ritonavir.<sup>1,2,3,4,5,6,7,8</sup> As such, product labeling for all antihepaciviral combination products (which contain ritonavir) lists use with ergot derivatives as contraindicated due to the risk of ergot toxicity.<sup>9,10</sup><br><br>The mechanism of this interaction is thought to be ritonavir inhibition of CYP3A-mediated ergot derivative metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Cagatay A, Guler O, Guven K. Ergotism caused by concurrent use of ritonavir and ergot alkaloids: a case report. <i>Acta Chir Belg</i>. 2009;109(5):639-640. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19994812\">[PubMed 19994812]</a></p>\n<p>2. Pardo Rey C, Yebra M, Borrallo M, Vega A, Ramos A, Montero MC. Irreversible coma, ergotamine, and ritonavir. <i>Clin Infect Dis</i>. 2003;37(5):e72-e73. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12942422\">[PubMed 12942422]</a></p>\n<p>3. Vila A, Mykietiuk A, Bonvehi P, Temporiti E, Uruena A, Herrera F. Clinical ergotism induced by ritonavir. <i>Scand J Infect Dis</i>. 2001;33(10):788-789. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11728055\">[PubMed 11728055]</a></p>\n<p>4. Spiegel M, Schmidauer C, Kampfl A, Sarcletti M, Poewe W. Cerebral ergotism under treatment with ergotamine and ritonavir. <i>Neurology</i>. 2001;57(4):743-744. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11524501\">[PubMed 11524501]</a></p>\n<p>5. Blanche P, Rigolet A, Gombert B, Ginsburg C, Salmon D, Sicard D. Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir. <i>Postgrad Med J</i>. 1999;75(887):546-547. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10616689\">[PubMed 10616689]</a></p>\n<p>6. Liaudet L, Buclin T, Jaccard C, Eckert P. Drug points: severe ergotism associated with interaction between ritonavir and ergotamine. <i>BMJ</i>. 1999;318(7186):771. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10082701\">[PubMed 10082701]</a></p>\n<p>7. Montero A, Giovannoni AG, Tvrde PL. Leg ischemia in a patient receiving ritonavir and ergotamine. <i>Ann Intern Med</i>. 1999;130(4 pt 1):329-330. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10068398\">[PubMed 10068398]</a></p>\n<p>8. Caballero-Granado FJ, Viciana P, Cordero E, Gomez-Vera MJ, del Nozal M, Lopez-Cortes LF. Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient. <i>Antimicrob Agents Chemother</i>. 1997;41(5):1207. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9145904\">[PubMed 9145904]</a></p>\n<p>9. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>10. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9662":"<p><b>Title</b> Cisapride / Antihepaciviral Combination Products</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Antihepaciviral Combination Products may increase the serum concentration of Cisapride. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of antihepaciviral combination products and cisapride. This combination is listed as contraindicated.</p>\n<div>\n <p><b>Antihepaciviral Combination Products Interacting Members</b> Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p>\n</div> \n<p><b>Discussion</b> The US and Canadian manufacturer of ombitasvir/paritaprevir/ritonavir/dasabuvir state that use with cisapride is contraindicated due to the potential for such concomitant therapy to cause serious cardiac arrhythmias (eg, torsades de pointes).<sup>1,2</sup> US labeling for ombitasvir/paritaprevir/ritonavir does not address an interaction with cisapride directly (likely due to its limited availability), but does state that use is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events.<sup>3</sup><br><br>The mechanism of this interaction is inhibition of the CYP3A-mediated metabolism of cisapride by antihepaciviral combination products.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Holkira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [product monograph]. St-Laurent, Quebec, Canada: AbbVie Corporation; December 2014.</p>\n<p>2. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; April 2016.</p>\n<p>3. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9663":"<p><b>Title</b> Flecainide / Antihepaciviral Combination Products</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: The management of this interaction differs between US and Canadian labeling.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antihepaciviral Combination Products may increase the serum concentration of Flecainide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased flecainide effects/toxicities if combined with an antihepaciviral combination product. Canadian labeling recommends avoiding this combination.</p>\n<div>\n <p><b>Antihepaciviral Combination Products Interacting Members</b> Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p>\n</div> \n<p><b>Discussion</b> US prescribing information for antihepaciviral combination products (ombitasvir/paritaprevir/ritonavir/dasabuvir and ombitasvir/paritaprevir/ritonavir) recommends additional monitoring for evidence of increased flecainide effects/toxicities when these agents are combined.<sup>1,2</sup> Canadian labeling for the antihepaciviral products recommends avoiding concomitant use with flecainide.<sup>3,4</sup> <br><br>The suspected primary mechanism of interaction between these agents is the inhibition of CYP3A4-mediated flecainide metabolism by antihepaciviral combination products, although CYP3A4 may only be a relevant factor in flecainide metabolism in patients taking CYP2D6 inhibitors or who are slow metabolizers of CYP2D6.<sup>3,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>2. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>3. Holkira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [product monograph]. St-Laurent, Quebec, Canada: AbbVie Corporation; December 2014.</p>\n<p>4. Technivie (ombitasvir/paritaprevir/ritonavir) [product monograph]. Saint-Laurent, Quebec, Canada: AbbVie Corporation; October 2015.</p>\n<p>5. Hu M, Yang YL, Fok BS, et al. Effects of CYP2D6*10, CYP3A5*3, CYP1A2*1F, and ABCB1 C3435T polymorphisms on the pharmacokinetics of flecainide in healthy Chinese subjects. <i>Drug Metabol Drug Interact</i>. 2012;27(1):33-39. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22718623\">[PubMed 22718623]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9664":"<p><b>Title</b> Propafenone / Antihepaciviral Combination Products</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: Avoid the use of antihepaciviral products and propafenone in patients who are also receiving CYP2D6 inhibitors.</p></li>\n <li><p><b>Genotype</b>: Avoid the use of antihepaciviral products and propafenone in patients who are poor CYP2D6 metabolizers.</p></li>\n <li><p><b>International labeling</b>: The management of this interaction differs between US and Canadian labeling.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antihepaciviral Combination Products may increase the serum concentration of Propafenone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased propafenone effects/toxicities if combined with an antihepaciviral combination product. Patients using such a combination should avoid the use of any CYP2D6 inhibitor, as the use of propafenone with both a CYP3A4 inhibitor (ie, antihepaciviral combination products) and a CYP2D6 inhibitor may result in an even greater risk for toxicity. Similarly, patients with genetically deficient CYP2D6 activity should avoid concurrent use of propafenone and a CYP3A4 inhibitor due to the potential for a significant increase in toxicity risk. <br><br>Canadian labeling recommends avoiding the combination of propafenone and antihepaciviral combination products.</p>\n<div>\n <p><b>Antihepaciviral Combination Products Interacting Members</b> Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p>\n</div> \n<p><b>Discussion</b> US prescribing information for antihepaciviral combination products (ombitasvir/paritaprevir/ritonavir/dasabuvir and ombitasvir/paritaprevir/ritonavir) recommends additional monitoring for evidence of increased propafenone effects/toxicities and monitoring of propafenone serum concentrations (if available) when these agents are combined.<sup>1,2</sup> Propafenone prescribing information states that the use of propafenone and CYP3A4 inhibitors (ie, antihepaciviral combination products) should be avoided in patients with impaired CYP2D6 activity or those taking CYP2D6 inhibitors.<sup>3</sup> Canadian labeling for the antihepaciviral products recommends avoiding concomitant use with propafenone.<sup>4,5</sup> <br><br>The suspected primary mechanism of interaction between these agents is the inhibition of CYP3A4-mediated propafenone metabolism by antihepaciviral combination products.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>2. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>3. Rythmol (propafenone) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; March 2013.</p>\n<p>4. Holkira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [product monograph]. St-Laurent, Quebec, Canada: AbbVie Corporation; December 2014.</p>\n<p>5. Technivie (ombitasvir/paritaprevir/ritonavir) [product monograph]. Saint-Laurent, Quebec, Canada: AbbVie Corporation; October 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9665":"<p><b>Title</b> Mexiletine / Antihepaciviral Combination Products</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antihepaciviral Combination Products may increase the serum concentration of Mexiletine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased mexiletine effects/toxicities if combined with an antihepaciviral combination product.</p>\n<div>\n <p><b>Antihepaciviral Combination Products Interacting Members</b> Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p>\n</div> \n<p><b>Discussion</b> Antihepaciviral US prescribing information recommends additional monitoring for evidence of increased mexiletine effects/toxicities and monitoring of mexiletine serum concentrations (if available) when these agents are used together, due to the potential for elevated serum mexiletine concentrations and associated toxicity.<sup>1,2</sup> <br><br>The suspected primary mechanism of an interaction between these agents is unclear, as mexiletine metabolism is mediated by CYP2D6 and CYP1A2, and antihepaciviral combination products strongly inhibit CYP3A4. Ritonavir has been shown to inhibit CYP2D6, but when used as part of antihepaciviral combination products, its effects on CYP2D6 are expected to be minimal.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>2. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>3. Holkira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [product monograph]. St-Laurent, Quebec, Canada: AbbVie Corporation, December 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9666":"<p><b>Title</b> Bepridil / Antihepaciviral Combination Products</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antihepaciviral Combination Products may increase the serum concentration of Bepridil. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased bepridil effects/toxicities if combined with an antihepaciviral combination product.</p>\n<div>\n <p><b>Antihepaciviral Combination Products Interacting Members</b> Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p>\n</div> \n<p><b>Discussion</b> US prescribing information for antihepaciviral combination products recommends additional monitoring for evidence of increased bepridil effects/toxicities when these agents are combined, due to the potential for elevated serum bepridil concentrations and associated toxicity.<sup>1,2</sup> <br><br>The suspected primary mechanism of interaction between these agents is inhibition of bepridil metabolism by antihepaciviral combination products.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>2. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9667":"<p><b>Title</b> Antihepaciviral Combination Products / Ketoconazole (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antihepaciviral Combination Products may increase the serum concentration of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Antihepaciviral Combination Products. Specifically, ketoconazole may increase serum concentrations of paritaprevir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Limit the dose of ketoconazole to 200 mg per day in patients taking antihepaciviral combination products. Additionally, monitor for increased ketoconazole effects/toxicities and for increased paritaprevir effects/toxicities.</p>\n<div>\n <p><b>Antihepaciviral Combination Products Interacting Members</b> Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the ombitasvir/paritaprevir/ritonavir/dasabuvir prescribing information, the coadministration of ombitasvir/paritaprevir/ritonavir/dasabuvir with ketoconazole (400 mg single dose) increased the ketoconazole AUC and maximum serum concentration (Cmax) 117% and 15%, respectively, in 12 healthy volunteers.<sup>1</sup> The paritaprevir AUC and Cmax increased 98% and 37%, respectively.<sup>1</sup> In a separate pharmacokinetic study described in the ombitasvir/paritaprevir/ritonavir prescribing information, the coadministration of ombitasvir/paritaprevir/ritonavir with ketoconazole (400 mg single dose) increased the ketoconazole AUC and maximum serum concentration (Cmax) 105% and 10%, respectively, in 12 healthy volunteers.<sup>2</sup> The paritaprevir AUC and Cmax increased 116% and 72%, respectively.<sup>2</sup><br><br>Inhibition of CYP3A4 by antihepaciviral combination products likely reduces CYP3A4-mediated ketoconazole metabolism, and inhibition of CYP3A4 by ketoconazole reduces CYP3A4-mediated paritaprevir metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>2. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9668":"<p><b>Title</b> Voriconazole / Antihepaciviral Combination Products</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antihepaciviral Combination Products may decrease the serum concentration of Voriconazole. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent use of voriconazole with antihepaciviral combination products should be avoided unless the patient-specific benefit/risk ratio justifies the use of voriconazole. Decreased efficacy of voriconazole is possible.</p>\n<div>\n <p><b>Antihepaciviral Combination Products Interacting Members</b> Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p>\n</div> \n<p><b>Discussion</b> The AUC of voriconazole was decreased 82% in healthy volunteers when voriconazole (400 mg every 12 hours day 1, then 200 mg every 12 hours) was coadministered with ritonavir (400 mg every 12 hours) for 9 days.<sup>1,2</sup> No significant effect on ritonavir pharmacokinetics was identified. Lower-dose ritonavir (100 mg every 12 hours) administered in a similarly designed study was associated with a 39% decrease in the AUC of voriconazole.<sup>1,2</sup> <br><br>The concomitant use of voriconazole and antihepaciviral combination products has not been studied, but based on the data with ritonavir (a component of antihepaciviral combination products), product labeling states that this combination should be avoided unless the patient-specific benefit/risk ratio justifies the use of voriconazole.<sup>3,4</sup><br><br>The likely mechanism for this apparent interaction is ritonavir-mediated induction of voriconazole metabolism, possibly via induction of CYP2C19. Voriconazole exposure appears to be affected to such a degree that therapeutic failure seems possible.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Vfend (voriconazole) [prescribing information]. New York, NY: Pfizer Inc; March 2008.</p>\n<p>2. Liu P, Foster G, Gandelman K, et al. Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. <i>Antimicrob Agents Chemother</i>. 2007;51(10):3617-3626. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17646413\">[PubMed 17646413]</a></p>\n<p>3. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>4. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9669":"<p><b>Title</b> AmLODIPine / Antihepaciviral Combination Products</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antihepaciviral Combination Products may increase the serum concentration of AmLODIPine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Reduce amlodipine dose by at least 50% and monitor for increased amlodipine effects (eg, hypotension) if an antihepaciviral combination product is initiated.</p>\n<div>\n <p><b>Antihepaciviral Combination Products Interacting Members</b> Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in product labeling, coadministration of ombitasvir/paritaprevir/ritonavir/dasabuvir and amlodipine (5 mg single dose) resulted in an increase in the amlodipine AUC and maximum serum concentration by 2.6-fold and 1.3-fold, respectively.<sup>1,2,3</sup><br><br>The suspected primary mechanism of this interaction is inhibition of the CYP3A4-mediated amlodipine metabolism by ombitasvir/paritaprevir/ritonavir/dasabuvir.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>2. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>3. Holkira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [product monograph]. St-Laurent, Quebec, Canada: AbbVie Corporation, December 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9670":"<p><b>Title</b> Furosemide / Antihepaciviral Combination Products</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Antihepaciviral Combination Products may increase the serum concentration of Furosemide. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required beyond the routine clinical monitoring that accompanies furosemide use.</p>\n<div>\n <p><b>Antihepaciviral Combination Products Interacting Members</b> Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in product labeling, coadministration of ombitasvir/paritaprevir/ritonavir/dasabuvir and furosemide (20 mg single dose) increased the furosemide maximum serum concentration and AUC by 42% and 8%, respectively, in 12 healthy volunteers.<sup>1,2</sup><br><br>The mechanism of this potential interaction is unknown, but UGT1A1 inhibition by antihepaciviral combination products may play a role, as UGT1A1 may play a role in furosemide metabolism.<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>2. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>3. Kerdpin O, Knights KM, Elliot DJ, Miners JO. In vitro characterisation of human renal and hepatic frusemide glucuronidation and identification of the UDP-glucuronosyltransferase enzymes involved in this pathway. <i>Biochem Pharmacol</i>. 2008;76(2):249-257. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18541222\">[PubMed 18541222]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9671":"<p><b>Title</b> Ombitasvir, Paritaprevir, and Ritonavir / Atazanavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Atazanavir may increase the serum concentration of Ombitasvir, Paritaprevir, and Ritonavir. Specifically, the paritaprevir component may increase significantly. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of atazanavir or atazanavir/ritonavir with the ombitasvir/paritaprevir/ritonavir combination product.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the product labeling for ombitasvir/paritaprevir/ritonavir, atazanavir (300 mg daily) given with ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg daily) increased the paritaprevir AUC, maximum concentration and minimum concentration 2.9-fold, 2.8-fold, and 3.8-fold, respectively, in 10 healthy volunteers.<sup>1</sup> Ombitasvir, ritonavir, and atazanavir concentrations were minimally effected.<sup>1</sup><br><br>Prescribing information for ombitasvir/paritaprevir/ritonavir states that due to the increases in paritaprevir concentrations, concomitant use with atazanavir or atazanavir/ritonavir should be avoided.<sup>1</sup><br><br>The mechanism of this interaction has not been fully investigated, but the increases in paritaprevir concentrations may be the result of increased CYP3A4 inhibition by atazanavir.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9672":"<p><b>Title</b> Darunavir / Ombitasvir, Paritaprevir, and Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ombitasvir, Paritaprevir, and Ritonavir may decrease the serum concentration of Darunavir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The ombitasvir/paritaprevir/ritonavir combination product can be combined with darunavir in treatment naive patients or in treatment experienced patients with no darunavir-associated mutations as long as the darunavir dose is 800 mg daily, darunavir is administered at the same time as the ombitasvir/paritaprevir/ritonavir combination product, and darunavir is given without additional ritonavir.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the ombitasvir/paritaprevir/ritonavir product label ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) given at the same time as darunavir (800 mg once daily) decreased the darunavir minimum concentration (Cmin) 26%, but had no effect on the AUC or maximum concentration (Cmax) of darunavir in 9 healthy subjects.<sup>1</sup> The AUC, Cmax, and Cmin of paritaprevir increased 2.1-fold, 1.9-fold, and 1.9-fold, respectively. The AUC of ritonavir decreased 20%, but the ritonavir Cmax and Cmin, as well as the ombitasvir pharmacokinetic parameters, were unchanged.<sup>1</sup><br><br>The prescribing information for the ombitasvir/paritaprevir/ritonavir combination product states that despite the reduction in the darunavir Cmin, these agents can be administered concomitantly in treatment naive patients or in treatment experienced patients with no darunavir-associated mutations as long as the darunavir dose is 800 mg daily, darunavir is given at the same time as the ombitasvir/paritaprevir/ritonavir product, and darunavir is given without additional ritonavir. Due to the risk of reduced darunavir concentrations, other dosing and administration strategies that have not been evaluated are not recommended.<br><br>The mechanism of this interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; March 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9673":"<p><b>Title</b> Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir / Atazanavir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Atazanavir may increase the serum concentration of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir. Specifically, the paritaprevir component may increase significantly. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The ombitasvir/paritaprevir/ritonavir/dasabuvir combination product can be combined with atazanavir as long as the atazanavir dose is 300 mg daily, atazanavir is administered in the morning at the same time as the ombitasvir/paritaprevir/ritonavir/dasabuvir combination product, and atazanavir is given without additional ritonavir. Patients should also be monitored for signs and symptoms of hyperbilirubinemia (eg, ocular icterus, jaundice) if these agents are combined.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the ombitasvir/paritaprevir/ritonavir/dasabuvir prescribing information, coadministration of atazanavir/ritonavir (300 mg/100 mg once daily in the evening) with ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily in the morning) and dasabuvir (250 mg twice daily) increased the paritaprevir AUC, maximum concentration, and minimum concentration by 3.2-fold, 2.2-fold, and 12-fold, respectively.<sup>1</sup> The AUC, Cmax and Cmin of ritonavir increased 3.2-fold, 1.6-fold, and 25-fold, respectively, and the AUC, Cmax, and Cmin of dasabuvir decreased 19%, 19%, and 20%, respectively.<sup>1</sup> The Cmax of ombitasvir decreased 17%, while the AUC and Cmin remained unchanged. The atazanavir AUC and Cmin increased 19% and 66%, respectively, while the Cmax was unchanged.<sup>1</sup><br><br>Product labeling for the ombitasvir/paritaprevir/ritonavir/dasabuvir prescribing information states that due to the increase in paritaprevir concentrations, these agents can be combined if the atazanavir dose is 300 mg daily, atazanavir is administered in the morning at the same time as the ombitasvir/paritaprevir/ritonavir/dasabuvir combination product, and atazanavir is given without additional ritonavir.<sup>1</sup> While the effect of this recommended dosing strategy on the pharmacokinetics of these agents has not been evaluated, this dosing regimen was used in a clinical trial of 63 patients co-infected with HIV and hepatitis C (HCV).<sup>1,2,3</sup> Sustained HCV virologic response rates were high (&gt; 90%) and no patients required a switch of their HIV regimen due to loss of HIV RNA suppression.<sup>1,2,3</sup> However, 17 patients (27%) had a total bilirubin level (mostly indirect) of more than 3 times the upper limit of normal and 15 of those 17 patients (88%) were taking concomitant atazanavir.<sup>2</sup> Six patients experienced ocular icterus, all occurring in patients receiving atazanavir, of whom 1 patient was switched to raltegravir-based ART in response to this event.<sup>2</sup><br><br>The mechanism of this interaction has not been fully investigated, but the increases in paritaprevir concentrations may be the result of increased CYP3A4 inhibition by atazanavir/ritonavir. Both atazanavir and the ombitasvir/paritaprevir/ritonavir/dasabuvir combination product are associated with increases in bilirubin. The combination of these agents may be additive.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>2. Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. <i>JAMA</i>. 2015;313(12):1223-1231. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25706092\">[PubMed 25706092]</a></p>\n<p>3. Eron JJ, Lalezari J, Slim J, et al. Safety and efficacy of ombitasvir - 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens. <i>J Int AIDS Soc</i>. 2014;17(4 suppl 3):19500. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25394009\">[PubMed 25394009]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9674":"<p><b>Title</b> Darunavir / Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir may decrease the serum concentration of Darunavir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the use of the ombitasvir/paritaprevir/ritonavir/dasabuvir combination product with darunavir/ritonavir in treatment experienced patients with one or more darunavir resistance substitutions or no baseline resistance information. <br><br>In treatment naive patients or treatment experienced patients with no darunavir resistance associated substitutions, darunavir 800 mg once daily (without ritonavir) can be co-administered with the ombitasvir/paritaprevir/ritonavir/dasabuvir combination product.</p> \n<p><b>Discussion</b> Three separate pharmacokinetic studies (N = 7 to 10) evaluated the concomitant use of the ombitasvir/paritaprevir/ritonavir/dasabuvir combination product and darunavir. In the first study, the darunavir (800 mg once daily) AUC, maximum concentration (Cmax), and minimum concentration (Cmin) decreased 24%, 8%, and 48%, respectively.<sup>1</sup> In the second study, coadministration with darunavir/ritonavir (darunavir 600 mg twice daily, ritonavir 100 mg once daily) decreased the darunavir AUC, Cmax, and Cmin by 20%, 13%, and 43%, respectively.<sup>1</sup> In the third study, coadministration with darunavir/ritonavir (800 mg/100 mg once daily) increased the darunavir AUC 34%, but decreased the darunavir Cmax and Cmin by 21% and 46%, respectively.<sup>1</sup><br><br>Product labeling for the ombitasvir/paritaprevir/ritonavir/dasabuvir combination product states that due to the reduction in the Cmin of darunavir, concomitant use with darunavir/ritonavir should be avoided in treatment experienced patients with unknown resistance information or at least one darunavir resistance substitution.<sup>1</sup> In treatment naive patients or treatment experienced patients with no darunavir resistance associated substitutions, darunavir 800 mg once daily (without ritonavir) can be co-administered with the ombitasvir/paritaprevir/ritonavir/dasabuvir combination product.<sup>1</sup> Reduced darunavir Cmins may be associated with therapeutic failure and/or the development of resistance. <br><br>The mechanism of this interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; March 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9675":"<p><b>Title</b> Antihepaciviral Combination Products / Lopinavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Lopinavir may increase the serum concentration of Antihepaciviral Combination Products. Specifically, the serum concentrations of the paritaprevir component may increase significantly. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of antihepaciviral combination products and lopinavir.</p>\n<div>\n <p><b>Antihepaciviral Combination Products Interacting Members</b> Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the ombitasvir/paritaprevir/ritonavir/dasabuvir prescribing information, the coadministration of ombitasvir/paritaprevir/ritonavir/dasabuvir with lopinavir/ritonavir (400 mg/100 mg twice daily) increased the paritaprevir AUC and maximum serum concentration (Cmax), and minimum serum concentration (Cmin) 2.2-fold, 2.0-fold, and 2.4-fold, respectively, in 6 healthy volunteers.<sup>1</sup> In a separate pharmacokinetic study, the coadministration of ombitasvir/paritaprevir/ritonavir/dasabuvir (given in the morning) with lopinavir/ritonavir (800 mg/200 mg once daily given in the evening) increased the paritaprevir AUC and Cmin 1.9-fold and 8.2-fold, respectively, in 12 healthy volunteers.<sup>1</sup> <br><br>In a pharmacokinetic study described in the ombitasvir/paritaprevir/ritonavir prescribing information, the coadministration of ombitasvir/paritaprevir/ritonavir with lopinavir/ritonavir (400 mg/100 mg twice daily) increased the paritaprevir AUC, Cmax, and Cmin 6.1-fold, 4.8-fold, and 12.3-fold, respectively, in 18 healthy volunteers.<sup>2</sup> In a separate pharmacokinetic study, the coadministration of ombitasvir/paritaprevir/ritonavir (given in the morning) with lopinavir/ritonavir (800 mg/200 mg once daily given in the evening) increased the paritaprevir AUC, Cmax, and Cmin 3.6-fold, 1.8-fold, and 14.8-fold, respectively, in 11 healthy volunteers.<sup>2</sup><br><br>Prescribing information for antihepaciviral combination products states that due to the increases in paritaprevir exposure, the concomitant use of antihepaciviral combination products with lopinavir/ritonavir should be avoided.<sup>1,2</sup><br><br>The mechanism of this interaction has not been fully investigated, but lopinavir/ritonavir inhibition of CYP3A4, an enzyme responsible for paritaprevir metabolism, likely contributes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>2. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9676":"<p><b>Title</b> Rilpivirine / Antihepaciviral Combination Products</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Antihepaciviral Combination Products may increase the serum concentration of Rilpivirine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of rilpivirine and antihepaciviral combination products.</p>\n<div>\n <p><b>Antihepaciviral Combination Products Interacting Members</b> Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the prescribing information, the coadministration of ombitasvir/paritaprevir/ritonavir/dasabuvir and rilpivirine (25 mg once daily) increased the rilpivirine AUC, maximum serum concentration, and minimum concentration 3.3-fold, 2.6-fold, and 3.6-fold, respectively, in 8 healthy volunteers.<sup>1,2</sup><br><br>Prescribing information for antihepaciviral combination products states that concomitant use with rilpivirine should be avoided due to the increased rilpivirine exposure and risk for QT prolongation.<sup>1,2</sup><br><br>The suspected mechanism of this interaction is antihepaciviral combination product-mediated CYP3A4 inhibition, an enzyme responsible for rilpivirine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>2. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9677":"<p><b>Title</b> Pravastatin / Antihepaciviral Combination Products</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antihepaciviral Combination Products may increase the serum concentration of Pravastatin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Limit the pravastatin dose to a maximum of 40 mg per day when used with antihepaciviral combination products and monitor patients for evidence of pravastatin toxicities (eg, myopathy).</p>\n<div>\n <p><b>Antihepaciviral Combination Products Interacting Members</b> Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the prescribing information, coadministration of ombitasvir/paritaprevir/ritonavir/dasabuvir with pravastatin (10 mg once daily) increased the pravastatin AUC and maximum serum concentration (Cmax) 82% and 37%, respectively, in 12 healthy subjects.<sup>1</sup> In a separate pharmacokinetic study of 10 healthy subjects, coadministration of ombitasvir/paritaprevir/ritonavir with pravastatin (10 mg once daily) increased the pravastatin AUC and Cmax 76% and 43%, respectively.<sup>2</sup><br><br>The most likely mechanism for this interaction is inhibition of the SLCO/OATP1B1 uptake transporter by paritaprevir, leading to reduced hepatic uptake of pravastatin.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>2. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9678":"<p><b>Title</b> Rosuvastatin / Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: US labeling recommends limiting the rosuvastatin dose to 10 mg per day. Canadian labeling recommends limiting the rosuvastatin dose to 5 mg per day.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir may increase the serum concentration of Rosuvastatin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Limit the rosuvastatin dose to a maximum of 10 mg per day when used with the ombitasvir/paritaprevir/ritonavir/dasabuvir combination product. Monitor patients closely for evidence of rosuvastatin toxicities (eg, myopathy). Canadian labeling recommends limiting the rosuvastatin dose to 5 mg per day.</p> \n<p><b>Discussion</b> The rosuvastatin AUC was an average of 2.59-fold higher with concurrent use of the ombitasvir/paritaprevir/ritonavir/dasabuvir combination product.<sup>1</sup> Based on these changes and concerns over an increased risk for rosuvastatin toxicities, the US prescribing information for the ombitasvir/paritaprevir/ritonavir/dasabuvir combination product recommends limiting the rosuvastatin dose to a maximum of 10 mg per day.<sup>1</sup> Canadian labeling recommends limiting the rosuvastatin dose to 5 mg per day.<sup>2</sup> <br><br>The most likely mechanism for this interaction is inhibition of the SLCO1B1 (aka OATP1B1) uptake transporter by paritaprevir leading to reduced hepatic uptake of rosuvastatin. The disposition of many statins, including rosuvastatin, appears to be at least somewhat dependent on the uptake transporter SLCO1B1, and paritaprevir has been shown to inhibit SLCO1B1 activity.<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc.; July 2015.</p>\n<p>2. Holkira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [product monograph]. St-Laurent, QC, Canada: AbbVie Corporation, December 2014.</p>\n<p>3. Kitamura S, Maeda K, Wang Y, Sugiyama Y. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. <i>Drug Metab Dispos</i>. 2008;36(10):2014-2023. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18617601\">[PubMed 18617601]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9680":"<p><b>Title</b> Fluvastatin / Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Canadian product labeling recommends use of the lowest fluvastatin dose with this combination, while US product labeling does not mention the possible interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir may increase the serum concentration of Fluvastatin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider monitoring for increased fluvastatin toxicity when coadministered with ombitasvir/paritaprevir/ritonavir/dasabuvir. Canadian product labeling recommends use of the lowest fluvastatin dose with this combination.</p> \n<p><b>Discussion</b> In clinical studies summarized in US and Canadian product labeling, use of the combination product containing ombitasvir, paritaprevir, ritonavir, and dasabuvir increased the AUCs of rosuvastatin and pravastatin by approximately 2.6 and 1.8 fold, respectively.<sup>1,2</sup> Although the mechanisms of these interactions are unclear, paritaprevir inhibition of statin hepatic uptake by SLCO1B1 and 1B3 (also known as OATP1B1 and 1B3) may contribute. The impact of paritaprevir on exposure to some other statins transported by SLCO1B1 and 1B3 (eg, pitavastatin, fluvastatin) has not been investigated.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc.; July 2015.</p>\n<p>2. Holkira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [product monograph]. St-Laurent, QC, Canada: AbbVie Corporation, December 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9681":"<p><b>Title</b> Pitavastatin / Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Canadian product labeling recommends use of the lowest pitavastatin dose with this combination, while US product labeling does not mention the possible interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir may increase the serum concentration of Pitavastatin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider monitoring for increased pitavastatin toxicity when coadministered with ombitasvir/paritaprevir/ritonavir/dasabuvir). Canadian product labeling recommends use of the lowest pitavastatin dose with this combination.</p> \n<p><b>Discussion</b> In clinical studies summarized in US and Canadian product labeling, use of the combination product containing ombitasvir, paritaprevir, ritonavir, and dasabuvir increased the AUCs of rosuvastatin and pravastatin by approximately 2.6 and 1.8 fold, respectively.<sup>1,2</sup> Although the mechanisms of these interactions are unclear, paritaprevir inhibition of statin hepatic uptake by SLCO1B1 and 1B3 (also known as OATP1B1 and 1B3) may contribute. The impact of paritaprevir on exposure to some other statins transported by SLCO1B1 and 1B3 (eg, pitavastatin, fluvastatin) has not been investigated.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc.; July 2015.</p>\n<p>2. Holkira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [product monograph]. St-Laurent, QC, Canada: AbbVie Corporation, December 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9682":"<p><b>Title</b> CycloSPORINE (Systemic) / Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir may increase the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> When initiating therapy with the ombitasvir/paritaprevir/ritonavir/dasabuvir combination product in patients taking cyclosporine, reduce cyclosporine dose 80% (ie, one-fifth of the current cyclosporine dose). Monitor cyclosporine blood concentrations to determine subsequent dose modifications. Upon completion of ombitasvir/paritaprevir/ritonavir/dasabuvir therapy, the appropriate time to resume the patient's previous dose of cyclosporine should be guided by assessment of cyclosporine blood concentrations. Frequent assessment of renal function and cyclosporine-related side effects is recommended.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the ombitasvir/paritaprevir/ritonavir/dasabuvir product label, when a single dose of cyclosporine was given to 10 healthy volunteers taking ombitasvir/paritaprevir/ritonavir/dasabuvir, the dose-normalized cyclosporine AUC and minimum concentration increased 5.8-fold and 15.8-fold, respectively.<sup>1,2</sup> <br><br>Product labeling for the ombitasvir/paritaprevir/ritonavir/dasabuvir combination product suggests an empiric 80% reduction in cyclosporine dose upon initiation of the ombitasvir/paritaprevir/ritonavir/dasabuvir product, and to monitor cyclosporine blood concentrations closely.<sup>1</sup> This dose reduction strategy was implemented in a clinical trial of the ombitasvir/paritaprevir/ritonavir/dasabuvir product in liver transplant recipients and resulted in similar cyclosporine blood concentrations before and after initiation.<sup>3</sup><br><br>The mechanism of this interaction has not been fully investigated, but ombitasvir/paritaprevir/ritonavir/dasabuvir inhibits CYP3A4 and P-glycoprotein, an enzyme and transporter responsible for cyclosporine metabolism and disposition.<sup>1,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>2. Badri P, Dutta S, Coakley E, et al. Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. <i>Am J Transplant</i>. 2015;15(5):1313-1322. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25708713\">[PubMed 25708713]</a></p>\n<p>3. Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. <i>N Engl J Med</i>. 2014;371(25):2375-2382. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25386767\">[PubMed 25386767]</a></p>\n<p>4. Neoral (cyclosporine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceutical Corporation; May 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9683":"<p><b>Title</b> Tacrolimus (Systemic) / Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir may increase the serum concentration of Tacrolimus (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid concomitant use of ombitasvir/paritaprevir/ritonavir/dasabuvir and tacrolimus. This combination is listed as contraindicated in product labeling. When these drugs were combined, the typical tacrolimus dose required to maintain therapeutic concentrations was only 0.5 mg every 7 days. Frequent assessment of renal function, tacrolimus blood concentrations, and tacrolimus-related side effects were required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the ombitasvir/paritaprevir/ritonavir/dasabuvir product label, a single dose of tacrolimus administered to 12 healthy volunteers taking ombitasvir/paritaprevir/ritonavir/dasabuvir increased the dose-normalized tacrolimus AUC and minimum concentration 57-fold and 17-fold, respectively.<sup>1,2</sup> <br><br>Product labeling for the ombitasvir/paritaprevir/ritonavir/dasabuvir combination product states that use with tacrolimus is contraindicated.<sup>1</sup> However, an initial tacrolimus dose reduction to 0.5 mg every 7 days was implemented in a clinical trial of the ombitasvir/paritaprevir/ritonavir/dasabuvir product in liver transplant recipients and resulted in similar tacrolimus blood concentrations before and during treatment.<sup>3,4</sup> <br><br>The mechanism of this interaction has not been fully investigated, but ombitasvir/paritaprevir/ritonavir/dasabuvir inhibits CYP3A4, an enzyme responsible for tacrolimus metabolism.<sup>1,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; March 2017.</p>\n<p>2. Badri P, Dutta S, Coakley E, et al. Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. <i>Am J Transplant</i>. 2015;15(5):1313-1322. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25708713\">[PubMed 25708713]</a></p>\n<p>3. Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. <i>N Engl J Med</i>. 2014;371(25):2375-2382. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25386767\">[PubMed 25386767]</a></p>\n<p>4. Badri PS, Parikh A, Coakley EP, et al. Pharmacokinetics of tacrolimus and cyclosporine in liver transplant recipients receiving 3 direct-acting antivirals as treatment for hepatitis C infection. <i>Ther Drug Monit</i>. 2016;38(5):640-645. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27310199\">[PubMed 27310199]</a> </p>\n<p>5. Prograf (tacrolimus) [prescribing information]. Northbrook, IL: Astellas Pharma US Inc; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9684":"<p><b>Title</b> CycloSPORINE (Systemic) / Ombitasvir, Paritaprevir, and Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ombitasvir, Paritaprevir, and Ritonavir may increase the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> When initiating therapy with the ombitasvir/paritaprevir/ritonavir combination product in patients taking cyclosporine, reduce the cyclosporine dose by 80% (ie, to one-fifth of the previous cyclosporine dose). Monitor cyclosporine blood concentrations to determine subsequent dose modifications. Upon completion of ombitasvir/paritaprevir/ritonavir therapy, the appropriate time to resume the previous dose of cyclosporine should be guided by assessment of cyclosporine blood concentrations. Frequent assessment of renal function and cyclosporine-related adverse effects is recommended.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the ombitasvir/paritaprevir/ritonavir product label, when a single dose of cyclosporine was given to 12 healthy volunteers taking ombitasvir/paritaprevir/ritonavir once daily, the dose-normalized cyclosporine AUC and minimum concentration increased 4.3-fold and 12.9-fold, respectively.<sup>1</sup> <br><br>Product labeling for the ombitasvir/paritaprevir/ritonavir combination product suggests an empiric 80% reduction in cyclosporine dose upon initiation of the ombitasvir/paritaprevir/ritonavir product, and to monitor cyclosporine blood concentrations closely.<sup>1</sup> This dose reduction strategy has not been evaluated with the ombitasvir/paritaprevir/ritonavir product, but was implemented in a clinical trial of the ombitasvir/paritaprevir/ritonavir/dasabuvir product in liver transplant recipients and resulted in similar cyclosporine blood concentrations before and after initiation.<sup>2</sup><br><br>The mechanism of this interaction has not been fully investigated, but ombitasvir/paritaprevir/ritonavir inhibits CYP3A4 and P-glycoprotein, an enzyme and transporter responsible for cyclosporine metabolism and disposition.<sup>1,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>2. Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. <i>N Engl J Med</i>. 2014;371(25):2375-2382. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25386767\">[PubMed 25386767]</a></p>\n<p>3. Neoral (cyclosporine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceutical Corporation; May 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9685":"<p><b>Title</b> Tacrolimus (Systemic) / Ombitasvir, Paritaprevir, and Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ombitasvir, Paritaprevir, and Ritonavir may increase the serum concentration of Tacrolimus (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of ombitasvir/paritaprevir/ritonavir and tacrolimus. This combination is listed as contraindicated in product labeling. When the ombitasvir/paritaprevir/ritonavir/dasabuvir product and tacrolimus were combined, the typical tacrolimus dose required to maintain therapeutic concentrations was only 0.5 mg every 7 days. Frequent assessment of renal function, tacrolimus blood concentrations, and tacrolimus-related side effects were required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the ombitasvir/paritaprevir/ritonavir product label, when a single dose of tacrolimus was given to 11 healthy volunteers taking ombitasvir/paritaprevir/ritonavir, the dose-normalized tacrolimus AUC and minimum concentration increased 86-fold and 25-fold, respectively.<sup>1</sup> <br><br>Product labeling for the ombitasvir/paritaprevir/ritonavir combination product states that use with tacrolimus is contraindicated.<sup>1</sup> However, an initial tacrolimus dose reduction to 0.5 mg every 7 days was implemented in a clinical trial of the ombitasvir/paritaprevir/ritonavir/dasabuvir product in liver transplant recipients and resulted in similar tacrolimus blood concentrations before and during treatment.<sup>2,3</sup> <br><br>The mechanism of this interaction has not been fully investigated, but ombitasvir/paritaprevir/ritonavir inhibits CYP3A4 and P-glycoprotein, an enzyme and transporter responsible for tacrolimus metabolism and disposition.<sup>1,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; March 2017.</p>\n<p>2. Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. <i>N Engl J Med</i>. 2014;371(25):2375-2382. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25386767\">[PubMed 25386767]</a></p>\n<p>3. Badri PS, Parikh A, Coakley EP, et al. Pharmacokinetics of tacrolimus and cyclosporine in liver transplant recipients receiving 3 direct-acting antivirals as treatment for hepatitis C infection. <i>Ther Drug Monit</i>. 2016;38(5):640-645. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27310199\">[PubMed 27310199]</a> </p>\n<p>4. Prograf (tacrolimus) [prescribing information]. Northbrook, IL: Astellas Pharma US Inc; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9686":"<p><b>Title</b> Omeprazole / Antihepaciviral Combination Products</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antihepaciviral Combination Products may decrease the serum concentration of Omeprazole. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased effects of omeprazole if combined with an antihepaciviral combination product. Omeprazole dose increases may be required.</p>\n<div>\n <p><b>Antihepaciviral Combination Products Interacting Members</b> Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the prescribing information, coadministration of ombitasvir/paritaprevir/ritonavir/dasabuvir with omeprazole (40 mg once daily) decreased the omeprazole AUC and maximum serum concentration (Cmax) 38% each in 11 healthy subjects.<sup>1</sup> In a separate pharmacokinetic study of 12 healthy subjects, coadministration of ombitasvir/paritaprevir/ritonavir with omeprazole (40 mg daily) decreased the omeprazole AUC and Cmax 46% and 48%, respectively.<sup>2</sup><br><br>Although not fully investigated, the suspected primary mechanism of this interaction is increased CYP2C19-mediated omeprazole metabolism due to CYP2C19 induction by the ritonavir component of antihepaciviral combination products.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>2. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>3. Dixit V, Hariparsad N, Li F, Desai P, Thummel KE, Unadkat JD. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. <i>Drug Metab Dispos</i>. 2007;35(10):1853-1859. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17639026\">[PubMed 17639026]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9687":"<p><b>Title</b> Phenytoin / NIFEdipine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Genotype</b>: PXR/NR1|2 haplotype appears to alter the inducibility of nifedipine metabolism.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> NIFEdipine may increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of NIFEdipine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid coadministration of nifedipine with strong CYP3A4 inducers such as phenytoin. Other dihydropyridine calcium channel blockers will likely interact with phenytoin to at least some degree.</p> \n<p><b>Discussion</b> According to data in nifedipine prescribing information, the mean nifedipine AUC was approximately 70% lower with concurrent use of the strong CYP3A4 inducer phenytoin.<sup>1</sup> Similarly, the mean nifedipine AUC and maximum serum concentration (Cmax) were reduced by 97% and 95%, respectively, when nifedipine (20 mg single dose) was given after 14 days of pretreatment with the strong CYP3A4 inducer rifampin (600 mg/day) in a study of 12 healthy volunteers.<sup>2</sup><br><br>These findings are consistent with those of published studies of healthy volunteers that have reported several-fold increases in nifedipine clearance, reduced nifedipine AUC, and/or substantially reduced nifedipine bioavailability when nifedipine was coadministered with rifampin or St John's wort.<sup>2,3,4,5</sup> Also, at least 2 published case reports highlight the likely clinical significance of this interaction. In one report, a patient with previously controlled hypertension on nifedipine experienced a loss of blood pressure control after starting rifampin.<sup>6</sup> Another patient who was taking nifedipine for control of angina also experienced a loss of nifedipine effectiveness shortly after starting concurrent rifampin.<sup>7</sup><br><br>The mechanism of this interaction appears to be induction of hepatic and intestinal CYP3A4, resulting in reduced nifedipine bioavailability. Data from one study that evaluated both oral and intravenous nifedipine support the key role of intestinal CYP3A4 in this interaction, finding little evidence for a substantial change in the hepatic extraction of nifedipine (but a large increase for gut wall extraction) and only a small impact on the pharmacokinetics of intravenous nifedipine.<sup>4</sup><br><br>Additionally, a case report described a patient whose serum phenytoin concentrations were approximately 3-fold higher with concurrent nifedipine.<sup>8</sup> The specific mechanism of this interaction is uncertain, but competition for CYP3A4 enzymes and/or alterations in hepatic blood flow caused by nifedipine-mediated vasodilation are possible mechanisms.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Procardia XL (nifedipine) [prescribing information]. New York, NY: Pfizer Inc; July 2013.</p>\n<p>2. Adalat (nifedipine) [prescribing information]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc; May 2008.</p>\n<p>3. Ndanusa BU, Mustapha A, Abdu-Aguye I. The effect of single does of rifampicin on the pharmacokinetics of oral nifedipine. <i>J Pharm Biomed Anal</i>. 1997;15(9-10):1571-1575. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9226591\">[PubMed 9226591]</a></p>\n<p>4. Holtbecker N, Fromm MF, Kroemer HK, Ohnhaus EE, Heidemann H. The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. <i>Drug Metab Dispos</i>. 1996;24(10):1121-1123. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8894514\">[PubMed 8894514]</a></p>\n<p>5. Wang XD, Li JL, Su QB, et al. Impact of the haplotypes of the human pregnane X receptor gene on the basal and St John's wort-induced activity of cytochrome P450 3A4 enzyme. <i>Br J Clin Pharmacol</i>. 2009;67(2):255-261. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19173680\">[PubMed 19173680]</a></p>\n<p>6. Tada Y, Tsuda Y, Otsuka T, et al. Case report: nifedipine-rifampicin interaction attenuates the effect on blood pressure in a patient with essential hypertension. <i>Am J Med Sci</i>. 1992;303(1):25-27. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1345893\">[PubMed 1345893]</a></p>\n<p>7. Tsuchihashi K, Fukami K, Kishimoto H, et al. A case of variant angina exacerbated by administration of rifampicin. <i>Heart Vessels</i>. 1987;3(4):214-217. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3453828\">[PubMed 3453828]</a></p>\n<p>8. Ahmad S. Nifedipine--phenytoin interaction. <i>J Am Coll Cardiol</i>. 1984;3(6):1582. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6425385\">[PubMed 6425385]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9689":"<p><b>Title</b> FentaNYL / Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Management of this interaction differs between US and Canadian labeling.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir may increase the serum concentration of FentaNYL. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> For patients who are receiving or have recently received ombitasvir/paritaprevir/ritonavir/dasabuvir, caution should be used in administering fentanyl. Monitor for increased opioid effects/toxicities (eg, sedation, respiratory depression) and consider using lower initial doses of fentanyl. Canadian labeling recommends avoidance of this combination.</p> \n<p><b>Discussion</b> No pharmacokinetic studies have been conducted between ombitasvir/paritaprevir/ritonavir/dasabuvir and fentanyl. However, since ombitasvir/paritaprevir/ritonavir/dasabuvir is a strong CYP3A4 inhibitor and CYP3A4 is primarily responsible for fentanyl metabolism, increased fentanyl exposure and effects are expected when these agents are used concomitantly.<br><br>US labeling for ombitasvir/paritaprevir/ritonavir/dasabuvir does not specifically address a potential interaction with fentanyl, but does state that combining ombitasvir/paritaprevir/ritonavir/dasabuvir with drugs that are substrates of CYP3A4 will likely lead to increased exposure and effects of the CYP3A4 substrate.<sup>1</sup> Canadian labeling states that the combination of ombitasvir/paritaprevir/ritonavir/dasabuvir and fentanyl should be avoided.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>2. Holkira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [product monograph]. St-Laurent, Quebec, Canada: AbbVie Corporation; December 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9690":"<p><b>Title</b> Alfentanil / Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Management of this interaction differs between US and Canadian labeling.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir may increase the serum concentration of Alfentanil. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> For patients who are receiving or have recently received ombitasvir/paritaprevir/ritonavir/dasabuvir, caution should be used in administering alfentanil. Monitor for increased anesthetic and respiratory depressant effects, and consider using lower initial doses of alfentanil, or an alternative anesthetic. Canadian labeling recommends avoidance of this combination.</p> \n<p><b>Discussion</b> No pharmacokinetic studies have been conducted between ombitasvir/paritaprevir/ritonavir/dasabuvir and alfentanil. However, since ombitasvir/paritaprevir/ritonavir/dasabuvir is a strong CYP3A4 inhibitor and CYP3A4 is primarily responsible for alfentanil metabolism, increased alfentanil exposure and effects are expected when these agents are used concomitantly.<br><br>US labeling for ombitasvir/paritaprevir/ritonavir/dasabuvir does not specifically address a potential interaction with alfentanil, but does state that combining ombitasvir/paritaprevir/ritonavir/dasabuvir with drugs that are substrates of CYP3A4 will likely lead to increased exposure and effects of the CYP3A4 substrate.<sup>1</sup> Canadian labeling states that the combination of ombitasvir/paritaprevir/ritonavir/dasabuvir and alfentanil should be avoided.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>2. Holkira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [product monograph]. St-Laurent, Quebec, Canada: AbbVie Corporation; December 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9691":"<p><b>Title</b> QuiNINE / Antihepaciviral Combination Products</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Antihepaciviral Combination Products may increase the serum concentration of QuiNINE. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of quinine and antihepaciviral combination products.</p>\n<div>\n <p><b>Antihepaciviral Combination Products Interacting Members</b> Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 10 healthy volunteers, the average AUC and maximum serum concentration of quinine increased approximately 4-fold when quinine (600 mg quinine sulfate single oral dose) was given on the eigth day of ritonavir administration (200 mg every 12 hours).<sup>1</sup><br><br>Prescribing information for quinine states that the use of quinine and ritonavir (and likely ritonavir containing products such as antihepaciviral combination products) should be avoided.<sup>2</sup><br><br>The mechanism of this interaction has not been investigated, but ritonavir-induced inhibition of CYP3A4, an enzyme responsible for quinine metabolism, likely contributes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Soyinka JO, Onyeji CO, Omoruyi SI, Owolabi AR, Sarma PV, Cook JM. Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration. <i>Br J Clin Pharmacol</i>. 2010;69(3):262-270. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20233197\">[PubMed 20233197]</a></p>\n<p>2. Qualaquin (quinine) [prescribing information]. Philadelphia, PA: Mutual Pharmaceutical Company Inc; July 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9692":"<p><b>Title</b> Riociguat / Antihepaciviral Combination Products</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antihepaciviral Combination Products may increase the serum concentration of Riociguat. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider starting with a reduced riociguat dose of 0.5 mg three times daily in patients who are also receiving drugs that are strong inhibitors of cytochrome P450 enzymes and P-glycoprotein/BCRP, such as the antihepaciviral combination products. Patients receiving any such combination should also be monitored closely for signs or symptoms of hypotension.</p>\n<div>\n <p><b>Antihepaciviral Combination Products Interacting Members</b> Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p>\n</div> \n<p><b>Discussion</b> According to the riociguat prescribing information, the average riociguat AUC and maximum serum concentration (Cmax) were approximately 2.5- and 1.5-fold greater, respectively, with concurrent use of ketoconazole, a strong inhibitor of cytochrome P450 isoenzymes and P-glycoprotein/BCRP.<sup>1</sup> The AUC and Cmax of the active riociguat metabolite (M1) were reduced by approximately 50% and by more than 20%, respectively.<br><br>The mechanism for this interaction is uncertain, but given the ability of ketoconazole to inhibit several different pathways that influence riociguat disposition, including multiple drug metabolizing enzymes (CYP1A, CYP3A, CYP2J2) and the P-glycoprotein drug transporter, it seems likely that ketoconazole inhibits the metabolism and/or transporter-related elimination of riociguat. The antihepaciviral combination products, strong inhibitors of CYP3A and inhibitors of P-glycoprotein and BCRP, would be expected to interact in a similar manner.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Adempas (riociguat) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; May 2014.</p>\n<p>2. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>3. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9693":"<p><b>Title</b> BuPROPion / Antihepaciviral Combination Products</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antihepaciviral Combination Products may decrease the serum concentration of BuPROPion. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased bupropion effects if combined with an antihepaciviral combination product. Following discontinuation of the antihepaciviral combination product, monitor for increased bupropion effects and toxicity. Avoid the use of naltrexone/bupropion for weight management in patients receiving ritonavir or ritonavir-containing products.</p>\n<div>\n <p><b>Antihepaciviral Combination Products Interacting Members</b> Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p>\n</div> \n<p><b>Discussion</b> Although the effect of combined use of an antihepaciviral combination product and bupropion has not been studied, ritonavir, a component of antihepaciviral combination products, has been studied in combination with bupropion. Ritonavir (400 mg twice daily) significantly decreased the bupropion AUC after both 3 days and 2.5 weeks (16% and 33% decrease vs control, respectively) of concurrent therapy in 13 healthy volunteers.<sup>1</sup> The ratio of hydroxybupropion (active metabolite)/bupropion was significantly increased, and the formation clearance of the hydroxybupropion metabolite was increased more than 2-fold after 2.5 weeks of ritonavir. In clinical studies summarized in naltrexone/bupropion US prescribing information, coadministration of ritonavir 100 mg daily for 17 days decreased the maximum concentration (Cmax) and AUC of bupropion by 21% and 22%, respectively, decreased the AUC of hydroxybupropion by 23%, and also decreased exposure to 2 other metabolites (threohydrobupropion and erythrohydrobupropion).<sup>2</sup> Coadministration of ritonavir 600 mg twice daily for 8 days decreased the Cmax and AUC of bupropion (62% and 66%, respectively), hydroxybupropion (42% and 78%, respectively), and the other metabolites to a greater extent.<sup>2</sup><br><br>Two weeks of combined lopinavir/ritonavir (400mg/100mg twice daily) decreased bupropion (single 100mg dose) AUC by 57% in a study of 12 healthy volunteers.<sup>3</sup> Hydroxybupropion AUC was also an average of 50% lower with ritonavir in this study. Conversely, a study of shorter-term ritonavir (200mg twice daily x 2 days) reported only minimal changes (less than 20%) of ritonavir on bupropion (and hydroxybupropion) in 7 healthy volunteers.<sup>4</sup><br><br>The suspected mechanism of this interaction is induction of bupropion metabolism via ritonavir-mediated CYP2B6 induction.<sup>1,3</sup> This is in contrast to in vitro data that had suggested ritonavir was an inhibitor of CYP2B6.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kharasch ED, Mitchell D, Coles R, Blanco R. Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. <i>Antimicrob Agents Chemother</i>. 2008;52(5):1663-1669. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18285471\">[PubMed 18285471]</a></p>\n<p>2. Contrave (naltrexone/bupropion) [prescribing information]. La Jolla, CA: Orexigen Therapeutics Inc; September 2014.</p>\n<p>3. Hogeland GW, Swindells S, McNabb JC, Kashuba AD, Yee GC, Lindley CM. Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects. <i>Clin Pharmacol Ther</i>. 2007;81(1):69-75. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17186001\">[PubMed 17186001]</a></p>\n<p>4. Hesse LM, Greenblatt DJ, von Moltke LL, Court MH. Ritonavir has minimal impact on the pharmacokinetic disposition of a single dose of bupropion administered to human volunteers. <i>J Clin Pharmacol</i>. 2006;46(5):567-576. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16638740\">[PubMed 16638740]</a></p>\n<p>5. Hesse LM, von Moltke LL, Shader RI, Greenblatt DJ. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. <i>Drug Metab Dispos</i>. 2001;29(2):100-102. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11159797\">[PubMed 11159797]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9694":"<p><b>Title</b> Linagliptin / Antihepaciviral Combination Products</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antihepaciviral Combination Products may increase the serum concentration of Linagliptin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor clinical response to linagliptin closely when used with antihepaciviral combination products. In particular, monitor for signs/symptoms of excessive response to linagliptin.</p>\n<div>\n <p><b>Antihepaciviral Combination Products Interacting Members</b> Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p>\n</div> \n<p><b>Discussion</b> According to study results cited in the linagliptin prescribing information, the average linagliptin AUC and maximum serum concentration (Cmax) were approximately 2-fold and 3-fold higher, respectively, when ritonavir (a component of antihepaciviral combination products) 200 mg twice daily and a linagliptin 5 mg single dose were coadministered.<sup>1</sup><br><br>The specific mechanism of this interaction is unclear, with inhibition of P-glycoprotein-mediated efflux of linagliptin a possible mechanism.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tradjenta (linagliptin) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; May 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9695":"<p><b>Title</b> OLANZapine / Antihepaciviral Combination Products</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antihepaciviral Combination Products may decrease the serum concentration of OLANZapine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients receiving this combination for reduced clinical effects of olanzapine.</p>\n<div>\n <p><b>Antihepaciviral Combination Products Interacting Members</b> Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 14 healthy volunteers, ritonavir (300 mg twice daily for 3 days, then 400 mg twice daily for 4 days, then 500 mg twice daily for 4 days) reduced the olanzapine (10 mg single oral dose) maximum concentration (Cmax), AUC, and half-life by 40%, 53%, and 50%, respectively.<sup>1</sup> In a study of 20 healthy volunteers, fosamprenavir/ritonavir (700 mg/100 mg orally twice daily for 16 days) reduced the dose-adjusted olanzapine (15 mg single oral dose with fosamprenavir/ritonavir or 10 mg single oral dose alone) Cmax and AUC by 12% and 33%, respectively, and decreased its half-life by 32%.<sup>2</sup><br><br>The suspected primary mechanism of these interactions is ritonavir induction of CYP1A2- and/or glucuronosyltransferase-mediated olanzapine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Penzak SR, Hon YY, Lawhorn WD, Shirley KL, Spratlin V, Jann MW. Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers. <i>J Clin Psychopharmacol</i>. 2002;22(4):366-370. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12172335\">[PubMed 12172335]</a></p>\n<p>2. Jacobs BS, Colbers AP, Velthoven-Graafland K, Schouwenberg BJ, Burger DM. Effect of fosamprenavir/ritonavir on the pharmacokinetics of single-dose olanzapine in healthy volunteers. <i>Int J Antimicrob Agents</i>. 2014;44(2):173-177. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24929949\">[PubMed 24929949]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9696":"<p><b>Title</b> Proguanil / Antihepaciviral Combination Products</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antihepaciviral Combination Products may decrease the serum concentration of Proguanil. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for reduced proguanil effectiveness when combined with antihepaciviral combination products.</p>\n<div>\n <p><b>Antihepaciviral Combination Products Interacting Members</b> Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p>\n</div> \n<p><b>Discussion</b> The proguanil AUC was an average of 38% and 41% lower, respectively, in HIV-positive patients stable on either lopinavir/ritonavir (800 mg/200 mg daily or 400 mg/100 mg twice/day; n=19) or atazanavir/ritonavir (300 mg/100 mg daily; n=19) than in healthy volunteers (n=18) when the groups were given a single dose of atovaquone/proguanil (250 mg/100 mg).<sup>1</sup> Though there were some notable differences between these study groups (HIV-status, HIV-positive patients were significantly older and more likely to be smokers), the magnitude of the observed difference suggests that a significant interaction may be likely.<br><br>The specific mechanism for this observed interaction is not clear. Ritonavir induction of the CYP2C19-mediated metabolism of proguanil may be at least partially responsible. The ritonavir-containing antihepaciviral combination products have not been studied with proguanil, but they have been shown to induce CYP2C19-mediated omeprazole metabolism.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. van Luin M, Van der Ende ME, Richter C, et al. Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir. <i>AIDS</i>. 2010;24(8):1223-1226. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20299957\">[PubMed 20299957]</a></p>\n<p>2. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>3. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9697":"<p><b>Title</b> Tacrolimus (Topical) / Ombitasvir, Paritaprevir, and Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ombitasvir, Paritaprevir, and Ritonavir may increase the serum concentration of Tacrolimus (Topical). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for elevated serum tacrolimus concentrations/toxic effects if ombitasvir/paritaprevir/ritonavir is initiated in patients using topical tacrolimus. The risk for systemic exposure and a significant drug interaction may increase with larger applied doses, larger treated areas, occlusion, facial or oral application, or application to inflamed or open lesions.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the ombitasvir/paritaprevir/ritonavir product label, when a single dose of oral tacrolimus was given to 11 healthy volunteers taking ombitasvir/paritaprevir/ritonavir, the dose-normalized tacrolimus AUC and minimum concentration increased 86-fold and 25-fold, respectively.<sup>1</sup><br><br>Blood concentrations are generally low (less than 1 ng/mL) when topical tacrolimus ointment is applied as indicated.<sup>2,3,4,5,6,7,8</sup> However, several cases of elevated blood concentrations (with or without systemic toxicity) have been reported with topical tacrolimus.<sup>9,10,11,12,13,14,15,16,17,18,19</sup> Authors have suggested that systemic exposure may increase with larger applied doses, larger treated areas, occlusion, facial or oral application, or application to inflamed or open lesions. The risk for and clinical significance of drug interactions involving topically applied tacrolimus will likely increase in the presence of these factors as well.<br><br>The mechanism of this interaction has not been fully investigated, but ombitasvir/paritaprevir/ritonavir inhibits CYP3A4 and P-glycoprotein, an enzyme and transporter responsible for tacrolimus metabolism and disposition.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>2. Protopic (tacrolimus) [prescribing information]. Deerfield, IL: Astellas Pharma US Inc; November 2011.</p>\n<p>3. Krueger GG, Eichenfield L, Goodman JJ, et al. Pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adult and pediatric patients with moderate to severe atopic dermatitis. <i>J Drugs Dermatol</i>. 2007;6(2):185-193. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17373177\">[PubMed 17373177]</a></p>\n<p>4. Draelos Z, Nayak A, Pariser D, et al. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison. <i>J Am Acad Dermatol</i>. 2005;53(4):602-609. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16198779\">[PubMed 16198779]</a></p>\n<p>5. Harper J, Smith C, Rubins A, et al. A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. <i>J Invest Dermatol</i>. 2005;124(4):695-699. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15816825\">[PubMed 15816825]</a></p>\n<p>6. Undre NA, Moloney FJ, Ahmadi S, Stevenson P, Murphy GM. Skin and systemic pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adults with moderate to severe atopic dermatitis. <i>Br J Dermatol</i>. 2009;160(3):665-669. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19076975\">[PubMed 19076975]</a></p>\n<p>7. Rubins A, Gutmane R, Valdmane N, Stevenson P, Foster C, Undre N. Pharmacokinetics of 0.1% tacrolimus ointment after first and repeated application to adults with moderate to severe atopic dermatitis. <i>J Invest Dermatol</i>. 2005;125(1):68-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15982304\">[PubMed 15982304]</a></p>\n<p>8. Alaiti S, Kang S, Fiedler VC, et al. Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children. <i>J Am Acad Dermatol</i>. 1998;38(1)69-76. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9448208\">[PubMed 9448208]</a></p>\n<p>9. Kameda G, Kramm C, Stege H, Hermsen D, Krutmann J, Niehues T. Unexpected high serum levels of tacrolimus after a single topical application in an infant. <i>J Pediatr</i>. 2003;143(4):280. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12970650\">[PubMed 12970650]</a></p>\n<p>10. Ghislain PD, De Decker I, Lachapelle JM. Efficacy and systemic absorption of topical tacrolimus used in pyoderma gangrenosum. <i>Br J Dermatol</i>. 2004;150(5):1052-1053. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15149540\">[PubMed 15149540]</a></p>\n<p>11. Kawashima M, Nakagawa H, Ohtsuki M, Tamaki K, Ishibashi Y. Tacrolimus concentrations in blood during topical treatment of atopic dermatitis. <i>Lancet</i>. 1996;348(9036):1240-1241. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8898050\">[PubMed 8898050]</a></p>\n<p>12. Allen DM, Esterly NB. Significant systemic absorption of tacrolimus after topical application in a patient with lamellar ichthyosis. <i>Arch Dermatol</i>. 2002;138(9):1259-1260. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12225004\">[PubMed 12225004]</a></p>\n<p>13. Allen A, Siegfried E, Silverman R, et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. <i>Arch Dermatol</i>. 2001;137(6)747-750. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11405764\">[PubMed 11405764]</a></p>\n<p>14. Pitarch G, Torrijos A, Mahiques L, Sanchez-Carazo JL, Fortea JM. Systemic absorption of topical tacrolimus in pyoderma gangrenosum. <i>Acta Derm Venereol</i>. 2006;86(1):64-65. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16585995\">[PubMed 16585995]</a></p>\n<p>15. Prot-Labarthe S, Therrien R, Champagne MA, Duval M, Joubert C. Toxic serum levels of tacrolimus after topical administration in an infant with severe cutaneous graft-versus-host disease. <i>Bone Marrow Transplant</i>. 2007;40(3):295-296. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17549052\">[PubMed 17549052]</a></p>\n<p>16. Russel RK, Richardson N, Wilson DC. Systemic absorption with complications during topical tacrolimus treatment for orofacial Crohn disease. <i>J Pediatr Gastroenterol Nutr</i>. 2001;32(2):207-208. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11321395\">[PubMed 11321395]</a></p>\n<p>17. Teshima D, Ikesue H, Itoh Y, Urabe K, Furue M, Oishi R. Increased topical tacrolimus absorption in generalized leukemic erythroderma. <i>Ann Pharmacother</i>. 2003;37(10):1444-1447. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14519034\">[PubMed 14519034]</a></p>\n<p>18. Beyerler M, Schmid-Grendelmeier P, Hafner J. Significantly elevated systemic levels after occlusive application of topical tacrolimus in atopic dermatitis. <i>Dermatology</i>. 2006;212(3):260-261. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16549924\">[PubMed 16549924]</a></p>\n<p>19. Conrotto D, Carrozzo M, Ubertalli AV, et al. Dramatic increase of tacrolimus plasma concentration during topical treatment for oral graft-versus-host disease. <i>Transplantation</i>. 2006;82(8):1113-1115. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17060865\">[PubMed 17060865]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9698":"<p><b>Title</b> Tacrolimus (Topical) / Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir may increase the serum concentration of Tacrolimus (Topical). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for elevated serum tacrolimus concentrations/toxic effects if ombitasvir/paritaprevir/ritonavir/dasabuvir is initiated in patients using topical tacrolimus. The risk for systemic exposure and a significant drug interaction may increase with larger applied doses, larger treated areas, occlusion, facial or oral application, or application to inflamed or open lesions.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the ombitasvir/paritaprevir/ritonavir/dasabuvir product label, when a single dose of tacrolimus was given to 12 healthy volunteers taking ombitasvir/paritaprevir/ritonavir/dasabuvir, the dose-normalized tacrolimus AUC and minimum concentration increased 57-fold and 17-fold, respectively.<sup>1,2</sup><br><br>Blood concentrations are generally low (less than 1 ng/mL) when topical tacrolimus ointment is applied as indicated.<sup>3,4,5,6,7,8,9</sup> However, several cases of elevated blood concentrations (with or without systemic toxicity) have been reported with topical tacrolimus.<sup>10,11,12,13,14,15,16,17,18,19,20</sup> Authors have suggested that systemic exposure may increase with larger applied doses, larger treated areas, occlusion, facial or oral application, or application to inflamed or open lesions. The risk for and clinical significance of drug interactions involving topically applied tacrolimus will likely increase in the presence of these factors as well.<br><br>The mechanism of this interaction has not been fully investigated, but ombitasvir/paritaprevir/ritonavir/dasabuvir inhibits CYP3A4 and P-glycoprotein, an enzyme and transporter responsible for tacrolimus metabolism and disposition.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>2. Badri P, Dutta S, Coakley E, et al. Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. <i>Am J Transplant</i>. 2015;15(5):1313-1322. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25708713\">[PubMed 25708713]</a></p>\n<p>3. Protopic (tacrolimus) [prescribing information]. Deerfield, IL: Astellas Pharma US Inc; November 2011.</p>\n<p>4. Krueger GG, Eichenfield L, Goodman JJ, et al. Pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adult and pediatric patients with moderate to severe atopic dermatitis. <i>J Drugs Dermatol</i>. 2007;6(2):185-193. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17373177\">[PubMed 17373177]</a></p>\n<p>5. Draelos Z, Nayak A, Pariser D, et al. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison. <i>J Am Acad Dermatol</i>. 2005;53(4):602-609. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16198779\">[PubMed 16198779]</a></p>\n<p>6. Harper J, Smith C, Rubins A, et al. A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. <i>J Invest Dermatol</i>. 2005;124(4):695-699. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15816825\">[PubMed 15816825]</a></p>\n<p>7. Undre NA, Moloney FJ, Ahmadi S, Stevenson P, Murphy GM. Skin and systemic pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adults with moderate to severe atopic dermatitis. <i>Br J Dermatol</i>. 2009;160(3):665-669. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19076975\">[PubMed 19076975]</a></p>\n<p>8. Rubins A, Gutmane R, Valdmane N, Stevenson P, Foster C, Undre N. Pharmacokinetics of 0.1% tacrolimus ointment after first and repeated application to adults with moderate to severe atopic dermatitis. <i>J Invest Dermatol</i>. 2005;125(1):68-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15982304\">[PubMed 15982304]</a></p>\n<p>9. Alaiti S, Kang S, Fiedler C, et al. Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children. <i>J Am Acad Dermatol</i>. 1998;38(1)69-76. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9448208\">[PubMed 9448208]</a></p>\n<p>10. Kameda G, Kramm C, Stege H, Hermsen D, Krutmann J, Niehues T. Unexpected high serum levels of tacrolimus after a single topical application in an infant. <i>J Pediatr</i>. 2003;143(4):280. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12970650\">[PubMed 12970650]</a></p>\n<p>11. Ghislain PD, De Decker I, Lachapelle JM. Efficacy and systemic absorption of topical tacrolimus used in pyoderma gangrenosum. <i>Br J Dermatol</i>. 2004;150(5):1052-1053. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15149540\">[PubMed 15149540]</a></p>\n<p>12. Kawashima M, Nakagawa H, Ohtsuki M, Tamaki K, Ishibashi Y. Tacrolimus concentrations in blood during topical treatment of atopic dermatitis. <i>Lancet</i>. 1996;348(9036):1240-1241. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8898050\">[PubMed 8898050]</a></p>\n<p>13. Allen DM, Esterly NB. Significant systemic absorption of tacrolimus after topical application in a patient with lamellar ichthyosis. <i>Arch Dermatol</i>. 2002;138(9):1259-1260. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12225004\">[PubMed 12225004]</a></p>\n<p>14. Allen A, Siegfried E, Silverman R, et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. <i>Arch Dermatol</i>. 2001;137(6)747-750. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11405764\">[PubMed 11405764]</a></p>\n<p>15. Pitarch G, Torrijos A, Mahiques L, Sanchez-Carazo JL, Fortea JM. Systemic absorption of topical tacrolimus in pyoderma gangrenosum. <i>Acta Derm Venereol</i>. 2006;86(1):64-65. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16585995\">[PubMed 16585995]</a></p>\n<p>16. Prot-Labarthe S, Therrien R, Champagne MA, Duval M, Joubert C. Toxic serum levels of tacrolimus after topical administration in an infant with severe cutaneous graft-versus-host disease. <i>Bone Marrow Transplant</i>. 2007;40(3):295-296. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17549052\">[PubMed 17549052]</a></p>\n<p>17. Russell RK, Richardson N, Wilson DC. Systemic absorption with complications during topical tacrolimus treatment for orofacial Crohn disease. <i>J Pediatr Gastroenterol Nutr</i>. 2001;32(2):207-208. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11321395\">[PubMed 11321395]</a></p>\n<p>18. Teshima D, Ikesue H, Itoh Y, Urabe K, Furue M, Oishi R. Increased topical tacrolimus absorption in generalized leukemic erythroderma. <i>Ann Pharmacother</i>. 2003;37(10):1444-1447. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14519034\">[PubMed 14519034]</a></p>\n<p>19. Beyerler M, Schmid-Grendelmeier P, Hafner J. Significantly elevated systemic levels after occlusive application of topical tacrolimus in atopic dermatitis. <i>Dermatology</i>. 2006;212(3):260-261. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16549924\">[PubMed 16549924]</a></p>\n<p>20. Conrotto D, Carrozzo M, Ubertalli AV, et al. Dramatic increase of tacrolimus plasma concentration during topical treatment for oral graft-versus-host disease. <i>Transplantation</i>. 2006;82(8):1113-1115. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17060865\">[PubMed 17060865]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9699":"<p><b>Title</b> Triamcinolone (Systemic) / Antihepaciviral Combination Products</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antihepaciviral Combination Products may increase the serum concentration of Triamcinolone (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients receiving triamcinolone during antihepaciviral combination product treatment for the development of Cushing syndrome and secondary adrenal insufficiency.</p>\n<div>\n <p><b>Antihepaciviral Combination Products Interacting Members</b> Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p>\n</div> \n<p><b>Discussion</b> Several case reports describe the development of exogenous Cushing syndrome and secondary adrenal insufficiency following triamcinolone injections (40 mg to 80 mg intramuscular, intra-articular, or epidural) administered to ritonavir-treated patients.<sup>1,2,3,4,5,6,7</sup> In these casese, low adrenocorticotropic hormone and cortisol concentrations, hyperglycemia, hypertension, weight gain, and other signs and symptoms persisted for 2 to 8 months. Unexpectedly high triamcinolone serum concentrations<sup>2,3,4</sup> and decreases in CD4 lymphocytes<sup>4,6,7</sup> were also reported in some cases.<br><br>The mechanism of this interaction has not been investigated, but ritonavir (a component of antihepaciviral combination products) may inhibit the metabolism of triamcinolone (eg, via CYP3A).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Levine D, Ananthakrishnan S, Garg A. Iatrogenic Cushing syndrome after a single intramuscular corticosteroid injection and concomitant protease inhibitor therapy. <i>J Am Acad Dermatol</i>. 2011;65(4):877-878. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21920248\">[PubMed 21920248]</a></p>\n<p>2. Danaher PJ, Salsbury TL, Delmar JA. Metabolic derangement after injection of triamcinolone into the hip of an HIV-infected patient receiving ritonavir. <i>Orthopedics</i>. 2009;32(6):450. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19634808\">[PubMed 19634808]</a></p>\n<p>3. Dort K, Padia S, Wispelwey B, Moore CC. Adrenal suppression due to an interaction between ritonavir and injected triamcinolone: a case report. <i>AIDS Res Ther</i>. 2009;8(6):10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19505306\">[PubMed 19505306]</a></p>\n<p>4. Ramanathan R, Pau AK, Busse KH, et al. Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir. <i>Clin Infect Dis</i>. 2008;47(12):e97-e99. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18991509\">[PubMed 18991509]</a></p>\n<p>5. Yombi JC, Maiter D, Belkhir L, Nzeusseu A, Vandercam B. Iatrogenic Cushing's syndrome and secondary adrenal insufficiency after a single intra-articular administration of triamcinolone acetonide in HIV-infected patients treated with ritonavir. <i>Clin Rheumatol</i>. 2008;27(suppl 2):S79-S82. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18827959\">[PubMed 18827959]</a></p>\n<p>6. Albert NE, Kazi S, Santoro J, Dougherty R. Ritonavir and epidural triamcinolone as a cause of iatrogenic Cushing's syndrome. <i>Am J Med Sci</i>. 2012;344(1):72-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22543594\">[PubMed 22543594]</a></p>\n<p>7. Grierson MJ, Harrast MA. Iatrogenic Cushing syndrome after epidural steroid injections for lumbar radiculopathy in an HIV-infected patient treated with ritonavir: a case report highlighting drug interactions for spine interventionalists. <i>PM R</i>. 2012;4(3):234-237. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22443962\">[PubMed 22443962]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}